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Regulatory T cells (Tregs) are key components of the
peripheral tolerance system and have become an
immunotherapeutic agent for treating inflammatory
processes. This therapeutic option, however, is hampered by
problems arising from isolating and expanding desirable
Tregs. Here we used an alternative approach with a
pharmacologic agent to stimulate Tregs to achieve
immunosuppressive effects. Pretreatment of mice with the
naturally occurring sphingosine N,N-dimethylsphingosine
(DMS) was found to increase both tissue-infiltrating T
effectors (Teffs, CD4þFoxp3) and Tregs (CD4þFoxp3þ ) in
the early phase of bilateral renal ischemia/reperfusion injury.
DMS itself had no effects on renal function or histopathology,
but rapidly and transiently increased both Teffs and Tregs
and increased the expression of chemokines CXCL9, CCL5,
and CXCL10 in non-ischemic kidneys (sham operation). This
renoprotection was abolished by administration of the Treg
suppressing agents, anti-CTLA-4 or anti-CD25 monoclonal
antibodies, suggesting that Tregs play a key role in DMS-
induced renoprotection. Thus, Tregs recruited to the kidney
by DMS ameliorate acute kidney injury and provide a new
approach to control inflammatory diseases.
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Regulatory T cells (Treg) have a central role in the
maintenance of immunological tolerance in the periphery
and have the potential to treat diseases by inhibiting
inflammatory processes.1,2 The infusion of Tregs is effective
in treating or preventing various experimental models
including rheumatoid arthritis,3 inflammatory bowel dis-
ease,4 systemic lupus erythematosus,5 graft versus host
disease,6 and others. However, this type of cellular therapy
is hampered by the problems arising from isolating and
expanding desirable Tregs. The alternative approach is to
use pharmaceutical agents to stimulate Tregs to achieve
immunosuppressive effects. Here we report that N,N-
dimethylsphingosine (DMS), a naturally occurring sphingo-
sine derivative, recruits Tregs to the kidney and ameliorates
ischemic acute renal injury (AKI) in a mouse ischemia/
reperfusion injury (IRI) model.
AKI is an increasingly common clinical problem with
high mortality and morbidity. Inflammation is a major
component of pathogenesis in ischemic AKI.7–9 Recently, we
have made a novel observation that T-cell infiltration occurs
as early as 1 h after renal IRI. This early and transient
T-cell infiltration can be blocked by SEW2871, a sphingosine-
1-phosphate receptor type 1 selective agonist, which inhibits
T-cell egress from secondary lymphoid organs. The blockage
of T-cell infiltration by SEW2871 is associated with
the amelioration of renal IRI,10 supporting the role of
T cells in AKI pathogenesis. More recently, it has been
evident that Tregs also have an important role in AKI.
Blocking Tregs worsens AKI, and infusion of Tregs protects
against AKI caused by IRI11,12 and nephrotoxic agent such as
cisplatin.13
In this study, we initially set to test whether DMS, a
known sphingosine kinase inhibitor,14 would have an
opposite effect as sphingosine-1-phosphate receptor type 1
agonist on ischemic AKI, i.e., increasing CD4þ T cells and
worsening renal damage. To our surprise, DMS increased
CD4þ T-cell infiltration but was renoprotective.
On further investigation, we demonstrated that DMS
recruited CD4þ Foxp3þ Tregs to the kidney, and that the
renoprotective effects were diminished by anti-CD25 and
anti-CTLA-4 antibodies, both known to suppress Treg
functions.
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RESULTS
DMS pretreatment ameliorates renal IRI
DMS (0.43mg/kg), given 10min before bilateral renal
ischemia, markedly reduced blood urea nitrogen (BUN,
Figure 1a) and serum creatinine (Cr, Figure 1b) levels after
24 h of reperfusion when compared with mice given vehicle
and sham operations. Renal IRI caused tubular necrosis,
tubular dilatation, and cast formation (Figure 1g), and
significant increase in neutrophil infiltration (Figure 1g,
arrows). DMS treatment markedly reduced tubular damage
(Figure 1h), and lowered acute tubular necrosis score (Figure
1c) and neutrophil infiltration (Figure 1d), 24 h after IRI.
Importantly, DMS treatment alone had no effects on
BUN, Cr levels, renal histology, or neutrophil infiltration
(Figure 1a–d and f).
DMS suppresses IR-induced upregulation of
proinflammatory cytokine TNFa
Renal IRI induces a surge in tissue levels of proinflammatory
cytokines, such as tumor necrosis factor-a (TNFa), causing
renal inflammation.15–17 To see whether DMS-mediated
renoprotective effect is associated with a reduction in TNFa
gene expression, TNFa mRNA abundance was measured by
quantitative reverse transcription-polymerase chain reaction
at 4 h after IRI. TNFa mRNA was increased by seven-fold,
and DMS reduced IRI-induced TNFa mRNA abundance by
more than 70% (Figure 2). However, DMS treatment does
not affect TNFa mRNA abundance in non-ischemic kidneys
(Figure 2).
DMS transiently recruits CD4þ T cells in both
non-ischemic and ischemic kidneys
To examine the relationship between T-cell infiltration and
DMS-induced renoprotection, we counted the number of
infiltrating CD4þ T cells on frozen sections of kidney using
immunofluorescence staining (red color in Figure 3a). As
there are very few CD4þ T cells in the non-ischemic kidney,
we counted T cells in the entire kidney cross-section (80–100
high-power fields (HPF) per section). In the ischemic kidney,
CD4þ cells increased at 1 h of reperfusion, remained
elevated at 4 h, and returned to the baseline at 24 h. DMS
pretreatment increased CD4þ T cells two-fold at 1 h
after reperfusion when compared with the IRI alone group
(Figure 3b). In non-ischemic kidney, CD4þ cells markedly
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Figure 1 |DMS ameliorates renal ischemia/reperfusion (IR)
injury. N,N-dimethylsphingosine (DMS) pretreatment (DMSþ IR)
significantly reduced blood urea nitrogen (BUN (a)), serum
creatinine (Cr (b)), acute tubular necrosis (ATN) scores (c, h), and
neutrophil infiltration (d, h) 24 h after IR injury, in comparison with
the IR only group (IR, g, arrows indicate neutrophils). DMS alone
(DMS, f) or sham-operated control (Control, e) had no effect on
renal biochemistry (a, b) and histopathological parameters (c, d).
For ATN scores (c) and neutrophil counts (d), values are
mean±s.e. Approximately 80 high-power fields (HPFs) per
individual mouse (20 HPFs per slide, four slides per animal) were
evaluated. n¼ 4–6 in each group. *Po0.01 vs. IR only.
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Figure 2 |DMS suppresses IR-induced upregulation of
proinflammatory cytokine TNFa. Induction of tumor necrosis
factor-a (TNFa) mRNA 4h after ischemia/reperfusion (IR) injury
was suppressed by N,N-dimethylsphingosine (DMS) pretreatment
(DMSþ IR). DMS alone (DMS) or sham-operated control (Control)
had no effect on TNFa mRNA abundance. TNFamRNA abundance
was measured by quantitative reverse transcription-polymerase
chain reaction, normalized to dynactin mRNA, and expressed as
fold relative to the controls (Control). **Po0.01 vs. controls,
#Po0.05 vs. IR only, n¼ 4–6 in each group.
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increased 1 h after injection of DMS, and then decreased at 4
and 24 h (Figure 3b). The finding that DMS protects against
renal IRI in the presence of increased T-cell infiltration seems
to contradict observations by us and others that CD4þ T
cells are essential for the pathogenesis of ischemic AKI.10,18
This paradox can be explained if this CD4þ T-cell
population includes Tregs that function as a suppressor
against T effectors (Teffs), thus achieving renoprotection
against IRI.
DMS recruits CD4þ Foxp3þ Tregs in both non-ischemic
and ischemic kidneys
To test the hypothesis that DMS may recruit Tregs to the
kidney, we counted the number of Tregs in the kidney slices
that were dual-stained with monoclonal antibodies (mAbs)
against anti-CD4 and anti-Foxp3, a specific marker for
Treg.19 The Foxp3 staining was highly concentrated in the
nucleus of Tregs (green color in Figure 3a), which is
consistent with its role as a master transcription factor for
T-cell suppression functions. Without DMS treatment, there
were some Teffs (CD4þ Foxp3) but very few Tregs
(CD4þ Foxp3þ ) in the ischemic kidneys (Figure 3a, insert
in the upper panel). DMS treatment increased the number of
CD4þ Foxp3þ Tregs in both non-ischemic (Figure 3a,
middle panel, 1 h after DMS injection) and ischemic kidneys
(Figure 3a, bottom panel, 1 h after reperfusion). Some
CD4þ Foxp3þ Tregs were found surrounded by
CD4þ Foxp3 Teff with direct cell–cell contacts (Figure 3a,
arrows, middle and lower panels).
The time course of changes in Tregs is shown in Figure 3c.
IRI alone had no effect on Tregs, in comparison with the
sham-operated controls. DMS transiently increased the
number of Tregs in non-ischemic and ischemic kidneys. In
non-ischemic kidneys, Tregs increased rapidly at 1 h (10-fold)
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Figure 3 |DMS enhances renal recruitment of CD4þ Foxp3þ T regulatory cells and CD4þ Foxp3 T effector cells. Panel a shows
representative immunofluorescence (IF) staining of ischemic kidney 1 h after reperfusion (ischemia/reperfusion (IR), upper panel),
N,N-dimethylsphingosine (DMS)-pretreated non-ischemic (DMS, middle panel) and ischemic kidneys (DMSþ IR, lower panel), using IF
staining with anti-CD4 (red), anti-Foxp3 (green) antibodies, and TO-PRO-3 iodide nuclear counterstain (blue). Panels b and c show the time
course of changes in total CD4þ cells and Tregs, respectively. Cell counts were expressed as number of cells per mm2 of kidney area.
d shows the time course of changes in renal Foxp3 mRNA abundance. Values are mean±s.e., n¼ 4–6 in each group. *Po0.05 vs. control;
**Po0.01 vs. control; #Po0.05 vs. IR only; ##Po0.01 vs. IR only.
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after injection of DMS, but returned to the baseline at 4 h. In
ischemic kidneys, DMS also increased Tregs at 1 h after
reperfusion. Treg count decreased at 4 h, but remained
elevated above the baseline at 4 and 24 h of reperfusion.
These results are consistent with the hypothesis that DMS
recruits the Tregs to the kidney. The recruitment of Tregs by
DMS is a dynamic process and ischemia causes retention of
Tregs in the injured kidney.
To independently confirm the increase in Tregs by DMS,
we measured Foxp3 mRNA in the kidney. After DMS
treatment, Foxp3 mRNA abundance increased at 1 h (2.5-
fold) and peaked at 4 h (3.6-fold) in the non-ischemic
kidneys (Figure 3d). In the ischemic kidneys, the DMS effect
was more significant (four-fold at 1 h and seven-fold at 4 h,
respectively, Figure 3d). As our immunofluorescence studies
show that Foxp3 is not expressed in the renal cells (Figure
3a), the increase in Foxp3 mRNA is presumably expressed by
the infiltrating CD4þ Foxp3þ Tregs. Collectively, our
findings confirm that Tregs are recruited to the kidney by
DMS. Notably, whereas the Foxp3 mRNA abundance was
highest at 4 h in the DMS-pretreated IRI kidney, the
CD4þ Foxp3þ Treg number is only moderately elevated.
The relatively high abundance of Foxp3 mRNA in these Tregs
suggests that Foxp3 may be upregulated in these active Tregs.
DMS administered after ischemia provides no protection
against IRI
When DMS was administered immediately after ischemia, it
provided no protection against IRI (Figure 4a and b). This
treatment did not affect total CD4þ cells measured 1 h after
reperfusion, but reduced the number of Tregs by 55% when
compared with the mice administered DMS before ischemia
(Figure 4d).
Anti-CTLA-4 or anti-CD25 mAb pretreatment abolishes DMS
renoprotection
To further delineate the role of Tregs on DMS-induced
renoprotection, we tested whether suppressing Tregs would
have an effect on DMS renoprotection. First, we used a
blocking mAb against CTLA-4, a surface marker and the
main mediator of Treg immunosuppression.20,21 CTLA-4
blockade abrogates in vitro Treg-mediated suppression and
abolishes Treg-mediated protection in a mouse inflammatory
bowel disease model.22,23 When DMS and the anti-CTLA-4
mAb 9H10 were administered simultaneously 10min before
the onset of ischemia, DMS-mediated renoprotection was
completely abolished, whereas a control immunoglobulin-G
(IgG) had no effect on DMS-mediated renoprotection
(Figure 5a–d).
Next, anti-CD25 mAb was used to deplete Tregs. CD25
(interleukin-2 receptor-a) is essential for the functional
160
120
80
BU
N 
(m
g/d
l)
Se
ru
m
 C
r (
mg
/dl
)
# 
CD
4+
 T
 c
el
l/m
m
2
40
0
2
1.6
16
14
12
10
8
6
4
2
0
2
2.5
1.5
1
0.5
0
1.2
*
*
0.8
0.4
0
IR DMS+IR IR+DMS
IR
*
*#
# 
CD
4+
Fo
xp
3+
 c
el
l/m
m
2
DMS+IR IR+DMS
IR DMS+IR IR+DMS
IR DMS+IR IR+DMS
*
Figure 4 |DMS administered after ischemia provides no
protection against IRI. N,N-dimethylsphingosine (DMS)
administered immediately after ischemia (ischemia/reperfusion
(IR)þDMS) provided no improvement in serum blood urea
nitrogen (BUN (a)) or creatinine (Cr (b)) level 24 h after injury, in
comparison with the IR only group (IR). There was no significant
difference in total CD4þ cells measured 1 h after reperfusion,
between the pretreated (DMSþ IR) and posttreated (IRþDMS)
groups (c). However, CD4þ Foxp3þ T regulatory number was
reduced by 55% in IRþDMS vs. DMSþ IR groups (d). *Po0.05 vs.
IR, #Po0.05 vs. DMSþ IR, n¼ 4–6 in each group.
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development and homeostasis of Tregs.24,25 Mice were
injected once with anti-CD25 mAb, PC61, which has been
shown to reduce Treg levels for up to 2 weeks.26 Three days
after anti-CD25 mAb injection, ischemia was initiated with
or without DMS pretreatment. PC61 treatment essentially
abrogated the DMS-mediated renoprotection effects, with
BUN, serum Cr, and acute tubular necrosis scores signifi-
cantly higher than those with the DMSþ IRI group or the
control IgG group (Figure 5a–d). To see whether the anti-
CTLA-4 or anti-CD25 mAb used in our experiments changes
the baseline level of kidney injury, mice were pretreated with
the above antibodies and then subjected to IRI without DMS
treatment. We found that anti-CTLA-4 or anti-CD25 mAb
did not affect serum BUN or Cr levels (Figure 6). Collectively,
these data suggest that Tregs have a major role in DMS-
mediated protection against renal IRI.
It has been reported that DMS directly inhibits neutrophil
activation by diverse stimuli in vitro.27 In vivo, DMS reduced
neutrophil infiltration at 24 h after IRI (Figure 1d). To
distinguish whether DMS reduces neutrophils through a
direct inhibitory effect or an indirect effect via Tregs, we
examined DMS effects on neutrophils in mice pretreated with
Anti-CD25 mAb, which reduces the number of Tregs without
affecting neutrophils.11 We found that in the presence of anti-
CD25 mAb DMS did not reduce neutrophil infiltration in
ischemic kidneys (anti-CD25 mAbþ IRI: 5.8±1.4 neutro-
phils/HPF; DMSþ anti-CD25 mAbþ IRI: 6.1±1.7 neutro-
phils/HPF, P40.05). These results indicate that the reduction
of neutrophil in ischemic kidneys by DMS is mediated by a
Treg-dependent mechanism.
Anti-CTLA-4 or anti-CD25 mAb pretreatment reduces
DMS-induced CD4þ Foxp3þ Tregs in the kidney
To see whether anti-CTLA-4 or anti-CD25 mAb pretreatment
has any effect on DMS-induced CD4þ T-cell or
CD4þ Foxp3þ Treg infiltration, cell counts were measured
in the ischemic kidneys. Anti-CTLA-4 and Anti-CD25 mAb
had no effect on DMS-induced CD4þ T-cell infiltration
(Figure 7a), but reduced CD4þ Foxp3þ Tregs by 35% and
50%, respectively (Figure 7b), when compared with the
DMSþ IRI group. The control IgG did not have any effect on
either CD4þ T cells or Tregs. To further evaluate the effects
of anti-CD25 mAb treatment on Treg depletion, we measured
spleen Tregs with flow cytometry. In the presence of IRI, anti-
CD25 mAb treatment reduced spleen CD4þ Foxp3þ cells
by 45%, whereas anti-CTLA-4 mAb had no effect on
CD4þ Foxp3þ Treg counts (Figure 8a and b). Our data
support other reports that anti-CD25 mAb treatment is
effective in suppressing Treg function despite the fact that it
only partially depletes the number of Tregs.26,28
Rapid and transient increase of chemokine expression in
DMS-treated kidney
It is well established that migration of T cells into peripheral
tissues is guided by chemokines secreted at the peripheral
sites in response to various stimulations.29,30 Chemokines
and their receptors are critical in directing the homing of
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Figure 5 |Anti-CD25 and anti-CTLA-4 treatment abolishes
renoprotective effects of DMS. Both anti-CTLA-4 and anti-CD25
treatments abolished renoprotective effects of N,N-
dimethylsphingosine (DMS), shown by the elevated blood urea
nitrogen (BUN (a)), serum Cr level (b), and acute tubular necrosis
(ATN) scores (c), whereas isotype immunoglobulin-G (IgG) did not
affect renoprotective effects of DMS. Representative renal
pathologies (d) show marked tubular damages in DMS-treated
mice with pretreatment of anti-CTLA-4 (upper panel) or anti-CD25
monoclonal antibody (middle panel) vs. pretreatment of isotype
IgG (lower panel). aCTLA-4: anti-CTLA-4; aCD25: anti-CD25. Values
are mean±s.e., n¼ 4–6 in each group. *Po0.05 vs. DMSþ IR.
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T cells to specific non-lymphoid tissues. For example, CCR5,
receptor for CCL5 (RANTES), and CXCR3, a receptor for
CXCL9 (MIG) and CXCL10 (IP10), are both shown to direct
Teffs and Tregs to the inflamed tissues.31,32 To see whether
DMS-induced T-cell infiltration is due to the induction of
tissue homing chemokines, we measured the total kidney
mRNA abundance of CXCL9, CCL5, and CXCL10 by
quantitative reverse transcription-polymerase chain reaction.
Rapid increase in mRNA abundance of CXCL9, CCL5, and
CXCL10 was shown within 1 h of DMS treatment, and the
level of CXCL9 mRNA remained elevated at 4 h (Figure 9).
These results suggest that increased chemokine expression in
the kidney may be the underlying mechanism for DMS-
induced Treg and Teff recruitment.
Lack of protection against IRI by specific sphingosine kinase
inhibitor 4-{[4-(4-chlorophenyl)-2-thiazoly]amino}phenol
DMS is a known sphingosine kinase inhibitor, but also has
effects on other kinases.33–35 To see whether DMS-mediated
protection against IRI is via the inhibition of sphingosine
kinase, we tested a specific sphingosine kinase inhibitor,
4-{[4-(4-chlorophenyl)-2-thiazoly]amino}phenol.36 As shown
in Figure 10, this inhibitor did not protect the kidney against
IRI at low (5mg/kg) or high dose (50mg/kg), suggesting that
the inhibition of sphingosine kinase alone does not account
for the DMS-mediated renoprotection.
DISCUSSION
Our study revealed several novel findings: (1) DMS
transiently recruits the Tregs and Teffs to the healthy kidney;
(2) IRI per se does not increase the number of Tregs in the
kidney within 24 h; (3) DMS increases the number of Tregs
and Teffs in IRI kidneys, but is renoprotective; (4) DMS-
mediated renoprotection is blocked by Anti-CTLA-4 mAb or
anti-CD25 mAb, which are known to suppress or deplete
Tregs; and (5) DMS increases chemokine expression rapidly
and transiently in the kidney. Our data show that we have
identified DMS as a novel reagent that effectively recruits
Tregs and protects the kidney against IRI.
It has been well established that AKI is an inflammatory
process, but the role of Tregs, the key regulatory cells of
inflammatory process, in protection against AKI has been
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recognized only recently. Blocking Tregs worsens AKI and
infusion of Tregs protects against AKI induced by IRI11,12 and
cisplatin, respectively.13 Our studies demonstrate that DMS, a
naturally occurring sphingosine derivative, transiently re-
cruits Tregs to the kidney and prevents renal IRI. Our studies
are consistent with the results of previous studies with Treg
infusion; furthermore, our novel approach has significant
advantage over infusion-based Treg therapy.
The timing of DMS administration is critical for renopro-
tection. When DMS was administered immediately after
reperfusion, its renoprotective effect was abolished. The loss
of the renoprotection was associated with a marked reduc-
tion in Treg levels (Figure 4d). Notably, the numbers of the
infiltrating Teffs were not significantly different irrespective of
whether DMS was given before or after ischemia (Figure 4c). It
is likely that when DMS is given after ischemia, its recruitment
of Tregs and Teffs is delayed, whereas IRI-induced Teff inflow
to the kidney is unchanged. These active Teffs may trigger a
cascade of inflammatory reactions to destroy the kidney,
which may not be curbed by the delayed arrival of Tregs.
The dosage of DMS used in experimental conditions is
crucial. DMS at a low dose has been used in mice to treat
anaphylatoxin-induced neutropenia and peritonitis.37 Using
the same dose (0.43mg/kg), we have demonstrated that DMS
induced Treg recruitment to the kidney and provided
renoprotection against IRI (Figures 1 and 3). However, using
a 10 times higher dose (5mg/kg), Lee and his co-workers38
showed detrimental effects on IRI when mice were anesthetized
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Figure 9 |Rapid and transient increase of chemokine
expression in N,N-dimethylsphingosine-treated kidney.
Total kidney mRNA abundance of CXCL9, CCL5, and CXCL10 was
measured by quantitative reverse transcription-polymerase chain
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relative to the controls (Control). *Po0.05 vs. untreated controls
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with isoflurane. One possibility for this remarkable dosage
effect is that DMS may exert cytotoxic effects at high
concentrations.
DMS is a versatile molecule with multiple biological
functions including inhibition of sphingosine kinase.33–35
Okusa’s group39 has demonstrated that IRI was not affected
by sphingosine kinase 1 knock out, but was worsened by
sphingosine kinase 2 knock out. Intuitively, these results
support the notion that sphingosine kinase inhibition is not
the key mechanism of DMS-mediated renoprotection. Using
a sphingosine kinase–specific inhibitor, 4-{[4-(4-chlorophe-
nyl)-2-thiazoly]amino}phenol, we further confirm that the
inhibition of sphingosine kinase alone does not account for
the DMS-mediated renoprotection.
The increase of Tregs by DMS in the kidney is most likely
caused by trafficking of existing Tregs, because CD4þ T cells
and CD4þ Foxp3þ Tregs peaked at 1 h after DMS treatment
and DMS upregulates the renal expression of CCL5, CXCL9,
and CXCL10. It is likely that DMS triggers the common
chemotactic mechanism shared by both Tregs and Teffs, thus
increasing both types of T cells in the kidney. DMS has been
shown to exert multiple biological functions such as
inhibiting protein kinase C,33 activating sphingosine-depen-
dent protein kinase 1,40 and mobilizing calcium,41 which may
also contribute to Treg trafficking to the kidney.
The results of experiments with anti-CTLA-4 and anti-
CD25 mAbs strongly indicate that Tregs recruited by DMS
have a key role in DMS-mediated renoprotection. CTLA-4
has a critical role in Treg-mediated immunosuppression.
Wing et al.21 demonstrated that Treg-specific CTLA-4
deficiency impairs in vivo and in vitro suppressive function
of Tregs and causes systemic lymphoproliferation, fatal
T cell–mediated autoimmune disease, and hyperproduction
of IgE in mice. Our finding that simultaneous administration
of anti-CTLA-4 mAb with DMS abolishes DMS-mediated
renoprotection, indicates that Treg-mediated immunosup-
pression is required for DMS effects. Interestingly, we found
that anti-CTLA-4 mAb treatment did not affect the total Treg
number in the spleen, but reduced kidney Treg infiltration
after IRI. It is possible that when CTLA-4 is blocked, the
recruited Tregs do not engage in cell–cell interactions with
Teffs and other inflammatory cells in the injured kidney.21
Therefore, the dwell time of Tregs in the kidney is shortened,
which may reduce the presence of Tregs in the kidney.
CD25 (interleukin-2 receptor-a) is essential for Treg
development and homeostasis of Tregs.24,25 Recently, anti-
CD25 mAb, PC61, was used to achieve partial depletion of
Treg and worsening of kidney IRI without any significant
effect on non-Treg cells in ischemic kidney, including B cells,
activated effector T cells, and natural killer cells, indicating
that anti-CD25 treatment is specific for Tregs.11 In our study,
we found that pretreatment with anti-CD25 mAb reduced
Treg recruitment to the kidney, increased neutrophil infiltra-
tion, and abolished the DMS-mediated renoprotection
against ischemic AKI. These results indicate that Tregs have
a pivotal role in DMS-mediated renoprotection against IRI.
In our anti-CD25 experiments, pretreatment with anti-
CD25 mAb did not worsen the baseline AKI. This is different
from a previous study showing worsening AKI.11 These
conflicting results may be due to the difference in ischemic
time (24min used in a previous study vs. 30min used in the
present study). The renoprotective effect of Tregs depends on
the number of Tregs; adoptive transfer of 1 106 Treg
provided more protection against ischemic AKI than 1 105
Tregs.12 Without adoptive transfer or DMS treatment, the
number of intrinsic Tregs in the kidney is low and Treg
number does not increase significantly after IRI (Figure 3c).
The low number of intrinsic Tregs may be sufficient to offer
protection against a mild injury but not severe injury. This
may explain why anti-CD25 mAb treatment worsened AKI
from 24min ischemia but not 30min ischemia.
Our studies focus on the role of Tregs in the prevention of
initial injury during IRI. Recently, other investigators have
reported that Tregs are important in the repair of AKI and in
precondition. Gandolfo et al.42 reported that infusion of Treg
1 day after ischemic AKI reduced interferon-g production by
Teffs at 3 days, improved repair and reduced cytokine
generation at 10 days. This post-ischemia repair can be
worsened by mycophenolate mofetil, which reduces renal T
cells, including Tregs.43 Kinsey et al.12 reported that nonlethal
ischemic injury increased the number of renal Tregs at day 7
of reperfusion and depletion of Tregs with PC61 abolished
precondition effects. Therefore, Tregs may have multiple roles
at different stages in protection of the kidney from IRI.
In conclusion, we have identified a novel Treg-recruiting
agent and demonstrated that Treg recruitment, probably
mediated by T-cell chemokines in the kidney, is associated
with the amelioration of ischemic AKI. This novel finding
has important clinical implications, as the pharmaceutical
recruitment of Tregs could circumvent the problems of
isolation and expansion of Tregs required for Treg infusion
therapy. In addition, transient pharmacological recruit-
ment of Tregs can be used clinically to suppress undesired
inflammatory reactions without long-term immunosuppres-
sion effects. DMS would be particularly useful in the setting
of kidney transplantation, as well as major cardiovascular
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Figure 10 | Lack of protection against IRI by specific
sphingosine kinase inhibitor (SKI). 4-{[4-(4-Chlorophenyl)-2-
thiazoly]amino}phenol, a specific inhibitor of sphingosine kinase,
did not protect the kidney against ischemia/reperfusion (IR) injury
(IRI) at low (5mg/kg) or high dose (50mg/kg) vs. vehicle controls.
Neither blood urea nitrogen (BUN) (a) or serum creatinine (Cr) (b)
level was affected by SKI pretreatment. Values are mean±s.e.,
n¼ 4–6 in each group.
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surgeries where AKI from ischemia–reperfusion frequently
occurs. DMS may be developed as the first-in-class Treg-
recruiting drug for treating or preventing not only AKI, but
also other inflammatory diseases.
MATERIALS AND METHODS
Animals and procedures
Male NIH Swiss mice (25–30 g) were purchased from the National
Cancer Institute. All animal procedures were approved by the
animal care committee of the University of Arizona and adhere to
the NIH Guide for the Care and Use of Laboratory Animals. DMS
(Sigma, St Louis, MO) was given at 0.43mg/kg body weight
intraperitoneally 10min before renal ischemia or at the time of
reperfusion. This dosage of DMS has been shown to exert protection
in anaphylatoxin C5A–triggered peritonitis.37 4-{[4-(4-chlorophe-
nyl)-2-thiazoly]amino}phenol (Cayman Chemical, Ann Arbor, MI)
was given at 5 or 50mg/kg body weight intraperitoneally 15min
before renal ischemia as described previously.38 Anti-CTLA-4
(9H10) and anti-CD25 (PC61) mAbs, and control IgG were
purchased from eBioscience (San Diego, CA), Chimerigen (Allston,
MA), and Sigma, respectively. For anti-CTLA-4 treatment, 9H10
mAb (10mg/kg body weight) was injected intraperitoneally 10min
before ischemia. For anti-CD25 treatment, PC61 mAb (10mg/kg
body weight) was injected intraperitoneally 3 days before ischemia
to allow time for Treg depletion. The renal ischemia (30min) and
reperfusion were performed as described previously.17 Mice were
killed at various time points after IRI and blood samples were
collected for BUN and Cr assays. The kidneys were excised and
processed for hematoxylin and eosin staining for histopathological
scoring, and immunofluorescence staining. The spleens were excised
and splenocytes were isolated for flow cytometry.
Histopathological examination for acute tubular necrosis
scores and neutrophil infiltration
Histological examinations for acute tubular necrosis scores and
neutrophil counts were performed in a blinded manner as described
previously.17 Acute tubular necrosis severity was semiquantified with
the following scoring system: 0¼ none, 1¼o10%; 2: 11–25%,
3¼ 26–45%, 4¼ 46–75%, and 5¼476%.44 At least 20 HPFs in the
corticomedullary junction per section ( 400 original magnifica-
tion) and four kidney sections from each mouse were examined.
Concurrently, neutrophil count was performed in the same fields.
Immunofluorescence staining
The sources of the primary and secondary antibodies and counter-
stain are anti-mouse CD4, anti-mouse Foxp3 (Biolegend, San Diego,
CA), Alexa Flour 488 anti-rabbit IgG (Hþ L) conjugate, Alexa Flour
594 anti-rat IgG (Hþ L) conjugate, and far-red fluorescence nuclear
counterstain TO-PRO-3 iodide (Molecular Probes, Carlsbad, CA).
Immunofluorescence staining was carried out as described pre-
viously.17 Images were captured with a confocal laser-scanning
microscopy system (BioRad MRC-500, Hercules, CA) attached to a
Nikon TMD-300 microscope (Melville, NY). Approximately 80–100
HPFs covering the entire kidney section ( 400 original magnifica-
tion) were examined in each slide blindly and four sections per
kidney from four to six mice in each group were examined.
Quantitative reverse transcription-polymerase chain reaction
Total RNA isolation and quantitative reverse transcription-poly-
merase chain reaction were performed as described previously.17
Dynactin 6 was used as an internal standard. Primer sequences used
for Dynactin 6, TNFa, CCL5, CXCL9, and CXCL10 have been
reported.10,17
Flow cytometry
The splenocytes were isolated from mice given sham operations
(control), anti-CD25þDMSþ IRI, anti-CTLA-4þDMSþ IRI, or
control IgGþDMSþ IRI. For mice with IRI, the spleens were
harvested 1 h after reperfusion. Single-cell splenocyte suspensions
were prepared by pressing the spleen through a nylon strainer
(BD Biosciences, San Jose, CA). Cells (106) were incubated with
fluorescein isothiocyanate–Foxp3 and phycoerythrin–CD4 mAb (BD
Biosciences) and analyzed using BD FACS Flow Cytometer equipped
with CellQuest Pro program (BD Biosciences).
Statistical analysis
Values are expressed as means±s.e. Student’s t-test was used to
compare differences in means. Multiple group comparisons were
made using analysis of variance with post-test according to
Bonferroni using the SPSS program (IBM, Armonk, NY). P-values
o0.05 were considered statistically significant.
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